Abstract
Herein, we sought to evaluate the potential of a recombinant Lactococcus lactis strain secreting the Yersinia pseudotuberculosis low-calcium response V (LcrV) antigen for mucosal vaccination against Yersinia infections. We showed that the recombinant strain induced specific systemic and mucosal antibody and cellular immune responses after intranasal immunization and protected mice against both oral and systemic Y. pseudotuberculosis infections. This constitutes the first proof of principle for a novel anti-Yersinia mucosal vaccination strategy using recombinant lactic acid bacteria.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Intranasal
-
Animals
-
Antibodies, Bacterial / analysis
-
Antibodies, Bacterial / blood
-
Antigens, Bacterial / genetics*
-
Antigens, Bacterial / immunology*
-
Bacterial Vaccines / administration & dosage
-
Bacterial Vaccines / genetics*
-
Bacterial Vaccines / immunology*
-
Colony Count, Microbial
-
DNA, Bacterial / chemistry
-
DNA, Bacterial / genetics
-
Female
-
Lactococcus lactis / genetics*
-
Liver / microbiology
-
Lymph Nodes / microbiology
-
Mice
-
Mice, Inbred BALB C
-
Molecular Sequence Data
-
Mucous Membrane / chemistry
-
Pore Forming Cytotoxic Proteins / genetics*
-
Pore Forming Cytotoxic Proteins / immunology*
-
Sequence Analysis, DNA
-
Spleen / microbiology
-
Survival Analysis
-
T-Lymphocytes / immunology
-
Yersinia pseudotuberculosis / genetics
-
Yersinia pseudotuberculosis / immunology
-
Yersinia pseudotuberculosis Infections / prevention & control*
Substances
-
Antibodies, Bacterial
-
Antigens, Bacterial
-
Bacterial Vaccines
-
DNA, Bacterial
-
LcrV protein, Yersinia
-
Pore Forming Cytotoxic Proteins